Federal funds can't be used to give test strips to drug users, raising overdose fears
By Ray Dombrowski ·
The story coming out of Washington isn’t about federal funds running short; it’s about ideology demanding a ledger line be drawn where life is concerned.
The Illusion of the Ledger Line
The story coming out of Washington isn’t about federal funds running short; it’s about ideology demanding a ledger line be drawn where life is concerned. SAMHSA issued sweeping guidance on April 24, 2026, prohibiting federal grants from purchasing fentanyl test strips and other drug-checking supplies. This policy shift—a dramatic reversal of earlier support—is framed by the Department of Health and Human Services (HHS) as a necessary move to ensure taxpayer money goes only to "effective, common-sense solutions." But when you audit that claim against reality, what you get is nothing but bureaucratic smoke.
The facts are concrete: test strips cost about $1 each. They take five minutes to use. And they provide an option. Candy Kerr of the Baltimore Harm Reduction Coalition stated plainly, “Nobody really knows what they're getting whenever they're getting stuff off of the street.” This isn’t a philosophical debate; it is public safety scored in payroll. The reporting from NPR highlighted that these strips help users check for dangerous adulterants like N-methylclonazepam—a benzodiazepine that doesn't respond to opioid overdose reversal drugs. When you see evidence, such as the three mass overdose incidents in Baltimore last year where follow-up testing revealed high levels of this specific drug, the value of knowing what you are using is undeniable.
The Cost of Withdrawal from Public Health Tools
The scope of the ban is breathtakingly wide. According to nwvcil.org and medicaltrainingnyc.com, SAMHSA has pulled funding not just for test strips, but also for sterile syringes, paraphernalia, and even overdose hotlines—which they characterize as "facilitating illicit drug use." This isn't a clean policy cut; it’s an amputation of established public health infrastructure.
The history of this fight is littered with reversals. As far back as April 2021, Tom Coderre had announced that federal funds could support test strip distribution. The decline in overdose deaths—which klinic.com notes dropped nearly 50% from their 2023 peak—is a trend built on decades of incremental, often underfunded, local efforts. These programs are already heavily reliant on state and city funding, which is precisely why the federal withdrawal hits so hard.
This pattern echoes the struggle faced during the HIV/AIDS epidemic. That global crisis required continuous, adaptive public health measures to keep pace with an evolving biological threat. The fight for effective treatment protocols—from early drug cocktails to modern antiretrovirals—was always a battle against funding mechanisms failing to keep up with scientific reality. In both cases, when political will dictates that the 'cost' of prevention is too high, the first thing cut are the tools that save lives on the ground.
The Audited Verdict
This policy isn't about law; it’s about punitive control disguised as fiscal responsibility. It assumes that people use drugs because they lack moral fiber, not because the economic and social structures have failed them. By restricting access to cheap, life-saving tools like test strips, Washington is betting against human survival. They are choosing an ideological purity over a payroll of living people. The only sustainable policy is one that treats public health as infrastructure—a utility paid for by the community, not dictated by the current administration's political ledger.